In embryonic stem cell (ESC) lines generated from human embryos determined through preimplantation genetic diagnosis to carry the fragile X mutation, the FMR1 gene is expressed in undifferentiated cells but undergoes transcriptional silencing after ESC differentiation (Eiges et al., 2007) . Here, we generated induced pluripotent stem cell (iPSC) lines from fibroblasts of individuals carrying the fragile X mutation. Despite successful reprogramming of the somatic cells to pluripotency, the FMR1 gene remained inactive and carried DNA methylation and histone modifications indicative of inactive heterochromatin. These data highlight critical differences between ESCs and iPSCs in modeling fragile X disorder.
Pluripotent stem cells are potentially an important tool to model human genetic disorders. Human embryonic stem cells can recapitulate early stages of human development, and they can also differentiate into cells from the three embryonic germ layers (Schuldiner et al., 2000; Thomson et al., 1998) . Thus, human pluripotent stem cells can be used to analyze the effect of specific mutations on the differentiation of various cell types and on early developmental processes that are otherwise inaccessible for research.
In the past few years, several diseases have been modeled in pluripotent stem cells, either by direct gene mutagenesis or by deriving ESCs from embryos determined by preimplantation genetic diagnosis (PGD) to carry genetic mutation (Eiges et al., 2007; Urbach et al., 2004;  reviewed in Lengerke and Daley, 2009) . Recently, human pluripotent stem cells have been derived from somatic cells by introduction of defined factors (Lowry et al., 2008; Park et al., 2008c; Takahashi et al., 2007; Yu et al., 2007) . These induced pluripotent stem cells (iPSCs) show remarkable similarity to human ESCs (Lowry et al., 2008; Park et al., 2008c; Takahashi et al., 2007; Yu et al., 2007) . By reprogramming somatic cells from patients, one may isolate pluripotent cells that harbor disease-specific mutations (Park et al., 2008a) . The reprogramming of somatic cells into pluripotent cells raised the question whether iPSCs will be able to replace human ESCs in basic research as well as in clinical applications (Belmonte et al., 2009) . We are now in a unique position to compare disease phenotypes manifest in ESCs to those seen in iPSCs.
Fragile X (FX) syndrome is the most common form of inherited mental retardation (Crawford et al., 2001; Rousseau et al., 1992) . It is caused by the absence of expression of the fragile X mental retardation 1 (FMR1) gene (O'Donnell and Warren, 2002) . The vast majority of FX patients do not express FMR1 resulting from CGG triplet repeat expansion in the 5 0 untranslated region of the gene (Pearson et al., 2005; Verkerk et al., 1991) . Full expansion of the CGG repeat usually coincides with hypermethylation of the repeat region and its upstream promoter (Oberle et al., 1991) , and with chromatin modifications such as histone H3 tail deacetylation, histone H3K9 methylation, and histone H3K4 demethylation (Coffee et al., 1999) . Until recently, early events in FMR1 silencing could not be characterized because of the lack of an appropriate animal model (Bontekoe et al., 1997; Lavedan et al., 1997) , but human ESCs have now been derived from FX blastocysts determined through preimplantation genetic diagnosis (PGD) (Eiges et al., 2007) . In the undifferentiated FXESCs, the full expansion of the CGG triplet repeat is not sufficient to inactivate the expression of the FMR1 gene and gene silencing occurs only upon differentiation (Eiges et al., 2007) . Evidence from chorionic villus samples supports a similar conclusion that transcriptional silencing of the FMR1 gene occurs with human development (Sutcliffe et al., 1992; Willemsen et al., 2002) . Current data suggest that upon cell differentiation, the mutated FMR1 gene recruits specific histone modifications followed by DNA methylation, which silence its transcription (Eiges et al., 2007; Pietrobono et al., 2005) .
In the current study we have isolated iPSC lines from three FX affected males and compared the regulation of FMR1 transcription to that of human FX-ESCs. Fibroblasts from 4-year-old and 28-yearold individuals, as well as fetal-lung fibroblasts from a 22-week-old affected fetus with FX syndrome, were reprogrammed in culture according to published protocols (Park et al., 2008b; Takahashi et al., 2007) . The efficiency of reprogramming of the FX-fibroblasts was similar to that of the WT-fibroblasts (0.0056% and 0.0024%, respectively), as determined by counting the number of Tra-1-60-positive colonies. Multiple FX-iPSC clones were analyzed (seven from the first, two from the second, and two from the third patient). The iPSC clones demonstrated typical characteristics of pluripotent stem cells: morphology similar to that of ESCs and expression of alkaline phosphatase, Tra-1-60, OCT4, SOX2, NANOG, SSEA3, SSEA4, and Tra-1-81 ( Figure S1A available online); silencing of retroviral transgenes ( Figure S1B and data not shown); reactivation of genes indicative of pluripotency (Figures S1C and S1D and data not shown); and maintenance of a normal diploid karyotype ( Figure S1E ). By hierarchical clustering and scatter plot analysis of DNA microarray results, we observed that the iPSCs cluster together with human ESCs and apart from their cell of origin ( Figures S2A and S2B ). The cells generated embryoid bodies ( Figure S2C , I) that expressed markers of endoderm ( Figure S2C , II and III), mesoderm (Figure S2C , IV and V), and ectoderm ( Figure S2C , VI) as demonstrated by immunostaining and also by RT-PCR (data not shown). The iPSC lines also differentiated in vivo into teratomas that manifest elements of all embryonic germ layers ( Figure S2D ). Thus, these human iPSC lines met stringent criteria for pluripotency (Chan et al., 2009; Daley et al., 2009) .
The FMR1 gene is expressed in FXESCs, WT-ESCs, wild-type skin fibroblasts, and iPSCs derived from them (Figure 1A) . The FMR1 gene is also expressed in wild-type lung fibroblasts (MRC5) and iPSCs derived from them (data not shown). In marked contrast to all of these cells, the FMR1 gene remained transcriptionally silent in all FX-iPSC clones derived from skin or lung FX-fibroblasts ( Figure 1A ). These results suggest that the differences in the expression of FMR1 between the WT and FX-iPSCs are due to the FMR1 mutation and not due to the tissue source of the original fibroblasts. The absence of FMR1 gene expression in the FX-iPSCs was observed both in early passage (P5) and at higher passages (up to P18; Figure 1B ), indicating a stable phenotype. The FX-iPSCs also lacked expression of the FMR1 protein by immunostaining ( Figure 1C) . Downregulation of the FMR1 gene occurs upon differentiation of human FXESCs, concomitant with downregulation of pluripotency-associated genes such as NANOG ( Figure 1D ; Eiges et al., 2007) . Interestingly, when differentiated cells derived from FX-ESCs were reverted to pluripotency by introduction of the reprogramming factors OCT4/SOX2/c-MYC/KLF4, they also failed to reactive FMR1 expression ( Figure 1D ). The CGG repeat length in the iPSCs derived from the differentiated FX-ESCs is in the same range as the FX-ESCs and the two subclones of FX-ESCs ( Figure 1E ). The data suggest that the silencing of the FMR1 in the FX-iPSCs is not due to expansion of the CGG repeats above that observed in FX-ESCs, where the gene is still active. The data also indicate that the reprogramming process has no major effect on the instability of the CGG repeats, because the reprogrammed cells have a similar number of repeats as their parental fibroblast ( Figure S2E) .
To examine the molecular basis for the silencing of FMR1 transcription in FX-iPSCs, we analyzed DNA methylation level at the FMR1 promoter by using bisulfite treatment followed by pyrosequencing in fibroblasts and in their derived iPSC lines. Pyrosequencing is an accurate and reliable method to determine the degree of methylation at several CpGs in close proximity with high quantitative resolution (Brakensiek et al., 2007; Dupont et al., 2004; Shaw et al., 2006; Tost and Gut, 2007; Wong et al., 2006) . While the FMR1 locus consistently lacked methylation in normal fibroblasts and their derivative iPSC lines, 8 of 9 FX-iPSC clones analyzed were highly methylated at levels comparable to the original fibroblasts; one iPSC clone (FX-iPS A-52) showed an intermediate methylation level, but still much higher than the WTfibroblasts and iPSCs (Figure 2A) . DNA methylation at the FMR1 locus persisted in the FX-iPSC clones despite the complete lack of methylation at the promoters for OCT4 ( Figures 2B and 2C ) We further explored histone modifications associated with transcriptionally active (H3 tail acetylation and lysine 4 methylation) and repressed (lysine 9 methylation) chromatin states associated with FMR1 silencing in somatic cells of FX individuals (Coffee et al., 1999 (Coffee et al., , 2002 Pietrobono et al., 2005) . We carried out chromatin immunoprecipitation (ChIP) experiments to analyze these modifications in two different FX-iPSC lines (#52 and #89). In contrast to the active chromatin marks on the FMR1 locus in FX-ESCs, normal ESCs, and normal iPSCs, the FMR1 locus in the FX-iPSCs is methylated at H3K9 and lacks histone acetylation and H3K4 methylation (Figure 2D) . Our data suggest that in FXiPSCs, the mutated FMR1 gene has chromatin modifications that are consistent with its transcriptionally silent state (see Figure S2F ).
Our results thus imply that the mutant FMR1 locus in FX-iPSC lines is resistant to activation by the iPSC reprogramming protocol. Although reversion of aberrant methylation, heterochromatin formation, and loss of FMR1 expression has not been studied during passage of the mutant allele through the germline in FRAXA families, conflicting data have been reported for the capacity to reactivate the silenced FMR1 gene in vitro. Two groups have shown that transfer of the X chromosome from FX patient cells into mouse embryonal carcinoma cells (Wö hrle et al., 2001) or fusion of FX cells with normal fibroblasts (Stoyanova et al., 2004) result in DNA demethylation and reactivation of the FMR1 gene, whereas a third group's attempt to reactivate the FMR1 gene by cell fusion with mouse embryonic carcinoma cells failed to erase the aberrant methylation of the mutant FMR1 gene (Burman et al., 1999a) . Similarly, de novo methylation of an unmethylated mutant FMR1 gene did not occur when inserted via microcell-mediated chromosome transfer into a mouse embryonal carcinoma cell line (Burman et al., 1999b) . Treatment of somatic FXfibroblasts with the demethylating agent 5-azacytidine has been shown to reactivate FMR1 expression . Apparently, under some circumstances the epigenetic marks that maintain silencing of a mutant FMR1 gene can be erased; however, the exact conditions that enable the reactivation of the FMR1 gene remain unclear. Although we cannot exclude the possibility that reprogramming cells from a different tissue or by a different method might reactivate FMR1 gene expression over time in FXiPSCs, the FMR1 locus seems to be highly resistant to the reprogramming process, according to current standard practice.
Human ESCs and iPSCs offer significant advantages for regenerative medicine (Amabile and Meissner, 2009; Mü ller et al., 2009; Nishikawa et al., 2008) and the modeling of human genetic disorders (Mü ller et al., 2009; Nishikawa et al., 2008; Park et al., 2008a) , although potential limitation such as chromosomal abnormalities (Baker et al., 2007; Lefort et al., 2008; Maitra et al., 2005; Spits et al., 2008) have to be considered before using the cells as a disease model. Our data highlight a significant difference between FX-ESCs and FX-iPSCs with regard to their expression of the FMR1 gene. The mutated FMR1 gene is expressed in FX-ESCs and transcriptionally silenced upon differentiation, whereas in FX-iPSCs the FMR1 locus remains inactive and is not reset by the reprogramming process to the transcriptionally active state. It is thus possible that other disorders related to epigenetic defects, including triplet repeat and imprinting disorders, may likewise evade the reprogramming process. Although FX-iPSCs do not model the differentiation-dependent silencing of the FMR1 gene, as shown for FX-ESCs, they may remain valuable for analyzing the role of FMR1 in neural cells. In FX-iPSCs, like in FX-neurons and in contrast to normal human iPSCs, the FMR1 gene is methylated, its chromatin is in a closed conformation, and the gene is not expressed. Therefore, differentiation of FX-iPSCs into neurons may nonetheless facilitate the study of FMR1 in neural cells. Until a deeper understanding of the potential differences between iPSCs and ESCs is delineated, the study of both iPSCs from patients and human ESCs carrying the same mutation (either from PGD embryos or by genetic manipulation) might, whenever possible, be the optimal approach to model human genetic disorders through cell culture. Finally, the distinction between FX-ESCs and FX-iPSCs at the FMR1 locus might be a particular example of a more general phenomenon of epigenetic differences between human ESCs and iPSCs, which highlights the need for more studies to clarify the similarity and differences between ESCs and iPSCs.
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